Aim and objectives To evaluate the effectiveness of alirocumab and evolocumab in reducing low density lipoprotein cholesterol (LDL-c) and RCE in patients with poorly controlled hyperlipidaemia. Material and methods This was an observational and retrospective study which included every patient treated with alirocumab and evolocumab between March 2016 and September 2019. Demographics and clinical variables were collected from the electronic medical records: sex, age, drug, dose, frequency of administration, previous hypolipaemic treatment, causes of suspension and analytical parameters at the start of treatment, and after 12 weeks and 24 weeks (total cholesterol (TC), LDL-c, high density lipoprotein (HDL)-cholesterol and triglycerides). To assess RCE, the Framingham scale was used, and if patients were diabetic or smokers was also recorded. To assess effectiveness, we calculated the percentage reduction (PR) of TC, LDL-c and RCE. Adverse effects (AE) were recorded to assess safety. Results Forty-six patients were included (76% men, average age 60.8 (SD 11.1) years: 24 were treated with alirocumab and 22 with evolocumab. Median duration of treatment was 27.2 months (0.2-43.8). At drug initiation, 71.7% of patients were on high dose statins and 76.1% were on ezetimibe as an adjuvant. Six patients discontinued treatment: 4 for toxicity, 1 for associated pathology and 1 due to loss of follow up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.